首页MOLN • NASDAQ
add
Molecular Partners AG
相关资讯
财务信息
损益表
收入
净收入
| (CHF) | 2025年9月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 360.20万 | -18.25% |
净收入 | -1183.60万 | 27.85% |
净利润率 | — | — |
每股收益 | -0.33 | 32.65% |
息税折旧摊销前利润 | -1140.30万 | 18.54% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (CHF) | 2025年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1.05亿 | -27.22% |
总资产 | 1.12亿 | -27.27% |
负债总额 | 1662.10万 | 7.70% |
权益总额 | 9552.90万 | — |
发行在外的股份 | 3739.92万 | — |
市净率 | 1.68 | — |
资产回报率 | -25.23% | — |
资本回报率 | -29.02% | — |
现金流
现金净变动
| (CHF) | 2025年9月info | 年同比变化 |
|---|---|---|
净收入 | -1183.60万 | 27.85% |
来自运营的现金 | -992.60万 | 25.27% |
投资现金 | 1066.40万 | -25.01% |
融资现金 | -30.40万 | -1.00% |
现金净变动 | 38.40万 | 481.82% |
自由现金流 | -540.11万 | 33.24% |
简介
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
成立时间
2004
员工数量
153
